LED Medical Diagnostics Inc.
TSX VENTURE : LMD
OTCQX : LEDIF
FRANKFURT : LME

LED Medical Diagnostics Inc.

October 29, 2013 08:30 ET

LED Medical Announces Canadian National Distribution Agreement with Sinclair Dental

BURNABY, BRITISH COLUMBIA--(Marketwired - Oct. 29, 2013) - LED Medical Diagnostics Inc. ("LED Medical, the Company")(TSX VENTURE:LMD)(OTCQX:LEDIF)(FRANKFURT:LME) is pleased to announce that it has entered into a partnership with Sinclair Dental ("Sinclair") for the distribution of the VELscope Vx® Enhanced Oral Assessment System.

"We are pleased to align ourselves with one of the fastest growing, full-service dental supply companies in Canada to expand distribution of the VELscope Vx® into more Canadian dental practices," commented David Gane, LED Medical's President and CEO. "Sinclair has an experienced team of over 500 individuals operating within 10 regional offices ready to represent our technology across the country. We are impressed with Sinclair's leadership within the industry and their responsiveness in bringing innovative solutions into the markets they serve."

As the most powerful technology available for assisting in the discovery of oral mucosal abnormalities, VELscope Vx® plays a key role in the early discovery of such abnormalities, which can be critically important in the fight against oral cancer. Detecting tissue abnormalities as early as possible is potentially life-saving, and VELscope Vx® technology is proven effective and minimally invasive and seamlessly can be implemented in a patient's routine dental check-ups.

Ali Nowtash, Sinclair's Director, Marketing & Purchasing said, "We are pleased to distribute the VELscope Vx system within the Canadian market. As the leader in the discovery of oral mucosal abnormalities, LED Medical has created significant awareness about oral cancer and the benefits of early diagnosis. We share LED's commitment to the early detection of lesions and tissue abnormalities and look forward to bringing this award-winning technology to our clients."

VELscope Vx®'s distinctive blue-spectrum light causes the soft tissues of the mouth to naturally fluoresce. Healthy tissues fluoresce in distinct patterns that are visibly disrupted by trauma or disease, such as neoplastic lesions, chemical irritation, side-effects from medication, thermal damage, fungal, viral or bacterial infections. Use of the VELscope Vx® allows a wide variety of oral abnormalities to be discovered, often before they're visible to the unassisted eye.

About Sinclair Dental

Proudly Canadian owned and operated, Sinclair is one of the fastest growing, full-service dental suppliers in Canada. The company's expansion has not compromised its tradition of quality products and exemplary service and it continually strives to be an industry leader focused on customer satisfaction, innovative solutions and being responsive to the industry's ever-changing trends and needs. For more details, visit www.sinclairdental.com.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.

Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope® Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, call 604.434.4614 or visit www.leddental.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Mark Komonoski, Investor Relations
    LED Medical Diagnostics Inc. (TSX.V: LMD, FSE: LME)
    (403) 255-8483 or Toll-Free: (877) 255-8483
    Cell: (403) 470-8384
    mark.komonoski@ledmd.com
    Skype: mkomonoski